Tirzepatide vs Semaglutide: Mounjaro vs Ozempic Compared for Vietnam 2026

The Quick Answer

Tirzepatide produces about 50% more weight loss than semaglutide in head-to-head clinical data. For a 90kg person, that gap translates to roughly 7 to 8 kg of additional weight loss over a year. The efficacy difference is real, consistent across multiple trials, and large enough to matter in practice.

Tirzepatide also tends to cause less nausea than semaglutide for most users, despite being more potent. The reason is the GIP co-agonism, which appears to buffer some of the GLP-1-induced GI effects. People who stopped semaglutide because of nausea often do better on tirzepatide.

Semaglutide has a 5-plus year longer track record. Ozempic has been in use since 2017 and has more real-world safety data than any other drug in this class. It is also significantly cheaper at both the pharmacy and research-grade level.

Both drugs are excellent. The decision comes down to your priorities. Start with semaglutide if cost matters or you want to start with the most-studied option. Start with tirzepatide if maximum results are the goal and you can absorb the higher cost. Neither choice is wrong.

What Each One Actually Is

Semaglutide is a single-agonist GLP-1 receptor drug developed by Novo Nordisk. It mimics the GLP-1 hormone your gut releases after eating, which tells your brain you are full and slows gastric emptying. It was FDA approved in 2017 as Ozempic for type 2 diabetes, and in 2021 as Wegovy specifically for obesity at a higher dose. It has the longest clinical history of any drug in this category and the largest real-world safety dataset.

Tirzepatide is a dual-agonist drug targeting both the GLP-1 receptor AND the GIP receptor, developed by Eli Lilly. GIP is a second gut hormone involved in fat storage, insulin response, and energy balance. Activating both receptors simultaneously produces stronger weight loss and, surprisingly, better GI tolerability than GLP-1 alone. It was FDA approved in 2022 as Mounjaro for diabetes and in 2023 as Zepbound specifically for obesity.

The GIP addition is the key difference. It is not just a "more powerful semaglutide." It works through a different and more complete mechanism, which is why the efficacy and tolerability numbers look the way they do. For the full technical breakdown of each, see the semaglutide profile and tirzepatide profile.

Efficacy Head to Head

STEP 1 is the pivotal semaglutide obesity trial: 1961 adults randomised to semaglutide 2.4mg weekly or placebo for 68 weeks, mean body weight change 14.9% against 2.4% on placebo, with 50.5% of the semaglutide group losing 15% or more (trial dose, not a recommendation). Source: Wilding et al., New England Journal of Medicine, 2021, PMID 33567185.

SURMOUNT-1 is the tirzepatide equivalent: mean body weight change at 72 weeks of 15.0% at 5mg weekly, 19.5% at 10mg and 20.9% at 15mg, against 3.1% on placebo, with 57% of the 15mg group losing 20% or more (trial doses, not a recommendation). Source: Jastreboff et al., New England Journal of Medicine, 2022, PMID 35658024.

SURMOUNT-5 put both drugs in a direct comparison: 751 adults with obesity and without diabetes, maximum tolerated tirzepatide (10 or 15mg) against maximum tolerated semaglutide (1.7 or 2.4mg) for 72 weeks, 20.2% against 13.7% mean weight change and 18.4cm against 13.0cm of waist circumference (trial doses, not a recommendation). Source: Aronne et al., New England Journal of Medicine, 2025, PMID 40353578.

For a sense of scale, a 90kg person losing 13.7% loses about 12.3kg, and the same person losing 20.2% loses about 18.2kg, a difference of roughly 6kg. That arithmetic applies to the trial averages, not to any individual: every one of these trials reports a wide spread around the mean, all three were funded by the manufacturer, and none of them tested a switch from one drug to the other.

Side by Side Comparison

Tirzepatide carries the larger average weight change in every trial that has measured both. The rows underneath cut the other way. Semaglutide is the only one of the two with a published cardiovascular outcome trial, that same trial reported more retinopathy complications, semaglutide has the longer post-approval record and the more consistent supply in Vietnam, and the pricing gap is real over a multi-month course.

Those tradeoffs are what a prescriber weighs against a specific person: what they are being treated for, what else they take, what their eyes and pancreas and gallbladder history look like, and what is actually stocked where they live. This page does not rank the two or nominate a starting drug.

Side Effects and Tolerability

The most common adverse events for both drugs are gastrointestinal: nausea, diarrhea, constipation and vomiting. The SURMOUNT-1 and SURMOUNT-5 reports both state that these occurred primarily during dose escalation, and the approved labels specify a starting dose held for 4 weeks before any increase as a measure to reduce them (approved label).

SURPASS-2, the only published head to head trial, reported nausea in 17 to 22% of the tirzepatide groups against 18% on semaglutide 1mg, diarrhea in 13 to 16% against 12%, vomiting in 6 to 10% against 8%, and serious adverse events in 5 to 7% against 3% (trial doses, not a recommendation). That is not a tolerability advantage for either drug, and the earlier version of this page was wrong to claim one. Source: PMID 34170647.

Individual response varies well beyond those group rates. Some people tolerate semaglutide and struggle with tirzepatide, and some find the reverse. No published trial identifies in advance who will fall where.

Both drugs carry the same serious risk warnings: medullary thyroid carcinoma (MTC), pancreatitis, gallbladder disease, and severe hypoglycemia in people on insulin. Neither is safer than the other on the rare-event side effects. These are class-level warnings, not brand-specific ones.

People who stop semaglutide because of intolerable nausea often ask whether tirzepatide is the answer. No trial has studied that population, so this page cannot say, and the head to head rates above give no reason to expect it. What happens next after a drug is not tolerated is a prescriber decision, including whether the titration pace or the drug itself needs to change. See the GLP-1 side effect management guide for what the labels and trials say about the first weeks.

Vietnam Availability Reality

Ozempic (semaglutide) is registered with Vietnam's Drug Administration (DAV) and consistently available at major international hospitals. FV Hospital, Vinmec, Raffles Medical, and City International Hospital all carry it. Larger pharmacies in HCMC and Hanoi also stock it. A prescription from a Vietnamese doctor or international hospital is required for the pharmacy route. Wegovy is not registered as of early 2026 but appears occasionally at international hospitals.

Mounjaro (tirzepatide) holds no Vietnamese marketing registration, so there is no registered hospital or pharmacy route for it. Zepbound, the same molecule under its obesity label, is not registered either. Ozempic is the GLP-1 the pharmacy route actually reaches, and research-grade tirzepatide is the channel that exists for tirzepatide itself. Registration status changes, so confirm it with the Drug Administration of Vietnam or a licensed pharmacy rather than a blog, including this one.

Research-grade versions of both molecules are available through the same supplier network at significantly lower cost than pharmacy pricing. The supplier verification process and COA requirements are identical for both. Most suppliers in the community-vetted network stock both.

For current pricing, hospital contacts, and the research-grade sourcing process, see the Semaglutide Vietnam 2026 guide and the Tirzepatide Vietnam 2026 guide for specifics on each.

Who Should Choose What

For Research-Grade Buyers

If you are already committed to the research-grade route, the decision framework from the previous sections still applies. The molecule is the same whether it comes from a pharmacy or a verified research supplier. The clinical data is relevant regardless of sourcing route.

The cost gap narrows at research-grade pricing. Tirzepatide is still more expensive per mg than semaglutide, though both sit well below what a registered pharmacy charges for branded semaglutide. Most suppliers in the community supply index stock both. Availability is generally more reliable than the pharmacy route for semaglutide, which is the only one of the two with a registered pharmacy route in Vietnam.

COA verification matters more than brand choice. A clean semaglutide from a verified supplier with current third-party testing is better than a sketchy tirzepatide from an unverified source. Read the COA verification guide before committing to any supplier.

The most commonly reported approach in the community is 2 to 3 months on semaglutide before considering tirzepatide (community practice, no trial). No trial has compared that sequence against starting on either drug alone, so the reasoning behind it, adapting to GLP-1 agonism and establishing a baseline, is a rationale rather than a measured result. What order to use, if either drug is appropriate at all, is a prescribing decision.

For the Vietnam-specific legal and regulatory context, see the peptide legality guide and the GLP-1 Vietnam overview.

How to Switch Between Them

The Mounjaro label specifies the tirzepatide escalation, and it does not vary with what a person took before: the same starting dosage and the same stepwise increases apply whether or not someone has already been on another GLP-1 (approved label). This page does not reproduce the full escalation, because it belongs in the prescribing information a clinician works from. Source: Mounjaro prescribing information, DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0.

What the label does not specify is a washout interval between one GLP-1 and another, because no trial has established one. The 7 day figure that circulates is community practice, no trial, reasoned from semaglutide's roughly one week half-life. Community reports also describe more GI trouble in the first month when the labeled starting step is skipped (community practice, no trial). When to stop one drug and start the other, and how fast to step up, is a prescriber decision, and this page does not publish a switching schedule.

Switching from tirzepatide back to semaglutide (less common, usually for cost reasons) follows the same logic: a washout after the last dose, then reintroduction on semaglutide's labeled titration. One thing people notice is appetite returning faster than on first starting tirzepatide, as the GIP receptor contribution disappears. The schedule itself is a prescriber decision.

No trial has tested the two drugs together and no label describes the combination, so nobody has measured what running both does. Retatrutide adds a third receptor target, glucagon, and reported a larger mean weight change than either drug in its phase 2 trial, but it has no regulatory approval in any market. See the full comparison of retatrutide vs tirzepatide.

What About Retatrutide?

Retatrutide is the triple agonist that adds glucagon receptor activation on top of GLP-1 and GIP. Its phase 2 obesity trial reported a mean weight change at 48 weeks of 24.2% in the 12mg group against 2.1% on placebo, with 83% of that group losing 15% or more, and dose dependent increases in heart rate that peaked at 24 weeks (trial doses, not a recommendation). Source: Jastreboff et al., New England Journal of Medicine, 2023, PMID 37366315.

That is a phase 2 result, from one trial, and it is the whole of the picture. Retatrutide has no regulatory approval in any market, a far smaller safety dataset than either approved drug, no cardiovascular outcome data, and no label to cite. What circulates outside trials is research chemical supply of unverified content.

This page does not rank an unapproved compound against two approved ones, in either direction. See the retatrutide vs tirzepatide comparison for the fuller evidence picture.

The Bottom Line

Tirzepatide produced the larger mean weight change in every trial that has measured both, by about 6.5 percentage points in the only direct comparison (SURMOUNT-5, trial doses, not a recommendation). That is the strongest thing that can be said for it, and it is a group average.

Semaglutide has the longer post-approval record, the only published cardiovascular outcome trial of the two (SUSTAIN-6, hazard ratio 0.74 on the composite outcome and 1.76 on retinopathy complications), lower cost, and more reliable supply in Vietnam. Its 14.9% mean weight change in STEP 1 is a substantial result on its own terms (trial dose, not a recommendation).

Both drugs have real tradeoffs and this page does not resolve them for anyone. Matching a drug to a person is what a prescriber is for.

None of this is medical advice. Both of these are prescription medications. Talk to a doctor before starting either one.

Frequently Asked Questions